In the complex world of pharmaceutical manufacturing, the quality and reliability of chemical intermediates are paramount. For companies involved in the production of antiviral medications, specifically HIV integrase inhibitors like Raltegravir, sourcing the correct intermediate is a crucial first step. This article focuses on Methyl 5-hydroxy-4-oxo-2-[2-(phenylmethoxycarbonylamino)propan-2-yl]-1H-pyrimidine-6-carboxylate, identified by its CAS number 519032-08-7.

This specific compound serves as a key building block in the multi-step synthesis of Raltegravir. Its chemical structure, C17H19N3O6, and molecular weight of 361.35 g/mol are precisely engineered to facilitate the subsequent reactions required to form the active pharmaceutical ingredient (API). The appearance of this intermediate is typically a white to off-white solid, with a notable melting point range of 186.3-187.0 °C, indicating its crystalline nature and purity.

For procurement managers and R&D scientists, understanding the specifications and sourcing options is vital. When looking to buy this pharmaceutical intermediate, it is essential to partner with reputable manufacturers and suppliers. Companies often search for terms like 'buy pharmaceutical intermediate CAS 519032-08-7,' 'Raltegravir intermediate supplier China,' or 'price of C17H19N3O6.' The availability of this compound from various manufacturers, particularly within China, offers competitive pricing and a diversified supply chain. For instance, when considering purchasing from a China-based manufacturer, buyers can expect a robust supply chain and potential cost advantages.

Beyond basic availability, quality assurance is a non-negotiable aspect. Pharmaceutical intermediates must meet stringent purity requirements, often exceeding 99.00%. Suppliers should be able to provide Certificates of Analysis (CoA), MSDS, and other relevant documentation to verify the quality and safety of the product. This rigorous approach ensures that the final API synthesized from this intermediate will meet all regulatory and therapeutic standards.

The synthesis process for CAS 519032-08-7 itself is a testament to the advancements in organic chemistry. While specific proprietary methods may vary, the general synthetic routes involve precise chemical reactions to assemble the complex pyrimidine core and its attached functional groups. The optimization of these processes by manufacturers aims to increase yield, reduce impurities, and lower production costs, ultimately benefiting the end-user by providing a more affordable and accessible medication.

In conclusion, for any pharmaceutical company involved in the Raltegravir supply chain, securing a consistent and high-quality source of Methyl 5-hydroxy-4-oxo-2-[2-(phenylmethoxycarbonylamino)propan-2-yl]-1H-pyrimidine-6-carboxylate (CAS 519032-08-7) is a strategic imperative. Engaging with experienced suppliers and manufacturers, particularly those with a strong presence in the global market, is key to ensuring product integrity and operational efficiency. When you need to purchase this critical intermediate, remember to prioritize purity, reliable supply, and competitive pricing from your chosen manufacturer.